ARTICLE | Product Development
Market reaction to Intellia data suggests perfection remains bar for gene editing
Clinical Report: Celldex advances in a second urticaria type, Eledon’s mAb helps Type I diabetes patients become insulin-independent, and more
October 29, 2024 11:10 PM UTC
Given the strength of its initial data, the latest results from Intellia’s Phase II study of NTLA-2002 to treat hereditary angioedema (HAE) disappointed investors, despite striking efficacy and a one-time dosing advantage that no competing therapeutic modality has offered HAE patients.
Shares of Intellia Therapeutics Inc. (NASDAQ:NTLA) fell 21% to $15.85 last Thursday, when the data were announced, and have not recovered, finishing at $14.99 on Tuesday...